|
|
 |
 |
 |
 |
 |
 |
|
|
Vladimir Novitsky
 Dr. Vladimir Novitsky is an HAI Research Scientist in the Harvard School of Public Health's Department of Immunology and infectious Diseases, where he has been researching the human immunodeficiency virus since 1996.
The majority of Dr. Novitsky's HIV research has examined HIV-1C, the subtype affecting populations in southern Africa. This research looks at the prospects and ideas for vaccine design for this particular subtype. Dr. Novitsky's work, particularly his investigative research of alleles specific to HIV in Botswana, is often conducted in conjunction with the research at the Botswana–HAI Partnership.
Another aspect of Dr. Novitsky's HIV-1C research involves the study of the immune system cells, known as cytotoxic T lymphocytes (CTLs), which kill foreign cells. CTLs play an important role in immune response: specific complexes on the surface of HIV-infected cells trigger CTLs to kill these infected cells, making CTL response a critical component of vaccine design. This CTL research provides new evidence that developing subtype-specific HIV-1 vaccine based on CTL is a sound approach for the design of an effective vaccine against AIDS.
In addition to his HIV-1C research, Dr. Novitsky has investigated issues related to the HIV-1A, HIV-1B, and HIV-1A/B subtypes. These subtypes are particularly prevalent in the Ukraine, Dr. Novitsky’s home country.
Co-author to nearly 20 publications, Dr. Novitsky received a doctor of medicine from the Priogov Medical Institution in Odessa, Ukraine and a doctorate in virology from the Ivanovsky Institute of Virology in Moscow, Russia.
|
|
|
